Anti-RNF139 antibody (500-550 aa) (STJ13101959)
SPECIFICATIONS
ClonalityPolyclonal
HostRabbit
ConjugationUnconjugated
IsotypeIgG
ImmunogenA synthetic peptide from aa region 500-550 of human RNF139 conjugated to an immunogenic carrier protein was used as the antigen. The peptide shares 95% identity with rat and mouse sequences.
General Information
| Short Description | Rabbit polyclonal anti-RNF139 (500-550 aa) for use in IHC and WB in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | IHC/WB |
| Host | Rabbit |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugation | Unconjugated |
| Purification | IgG purified |
| Dilution Range | IHC, WB (confirmed by recombinant protein). A dilution of 1: 300 to 1:2000 is recommended. The optimal dilution should be determined by the end user. Not yet tested in other applications. |
| Formulation | Lyophilised |
| Storage Instruction | Maintain the lyophilised/reconstituted antibodies frozen at-20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, Glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles. |
Target Information
| Gene Symbol | RNF139 |
| Gene ID | 11236 |
| Uniprot ID | RN139_HUMAN |
| Immunogen | A synthetic peptide from aa region 500-550 of human RNF139 conjugated to an immunogenic carrier protein was used as the antigen. The peptide shares 95% identity with rat and mouse sequences. |
| Immunogen Region | 500-550 aa |
| Specificity | Specific for RNF139. |
Additional Info
| Post Translational Modifications | Autoubiquitinated. Ubiquitination is induced by sterol and leads to ist degradation via the ubiquitin-proteasome pathway. |
| Function | E3-ubiquitin ligase.acts as a negative regulator of cell proliferation through mechanisms involving G2/M arrest and cell death. Required for MHC class I ubiquitination in cells expressing the cytomegalovirus protein US2 before dislocation from the endoplasmic reticulum (ER). Affects SREBP processing by hindering the SREBP-SCAP complex translocation from the ER to the Golgi, thereby reducing SREBF2 target gene expression. Involved in the sterol-accelerated degradation of HMGCR. This is achieved through binding of RNF139 to INSIG1 and/or INSIG2 at the ER membrane. In addition, interaction of RNF139 with AUP1 facilitates interaction of RNF139 with ubiquitin-conjugating enzyme UBE2G2 and ubiquitin ligase AMFR, leading to ubiquitination of HMGCR. The ubiquitinated HMGCR is then released from the ER into the cytosol for subsequent destruction. Required for INSIG1 ubiquitination. May be required for EIF3 complex ubiquitination. |
| Protein Name | E3 Ubiquitin-Protein Ligase Rnf139Ring Finger Protein 139Ring-Type E3 Ubiquitin Transferase Rnf139Translocation In Renal Carcinoma On Chromosome 8 Protein |
| Database Links | Reactome: R-HSA-901032 |
| Cellular Localisation | Endoplasmic Reticulum MembraneMulti-Pass Membrane Protein |
| Alternative Antibody Names | Anti-E3 Ubiquitin-Protein Ligase Rnf139 antibodyAnti-Ring Finger Protein 139 antibodyAnti-Ring-Type E3 Ubiquitin Transferase Rnf139 antibodyAnti-Translocation In Renal Carcinoma On Chromosome 8 Protein antibodyAnti-RNF139 antibodyAnti-TRC8 antibody |
Information sourced from Uniprot.org